Prevalence of atrial fibrillation and antithrombotic prophylaxis in emergency department patients

被引:50
作者
Scott, PA
Pancioli, AM
Davis, LA
Frederiksen, SM
Eckman, J
机构
[1] Univ Michigan, Dept Emergency Med, Ann Arbor, MI 48109 USA
[2] Univ Cincinnati, Cincinnati, OH USA
[3] NINDS, NIH, Div Diagnost & Therapeut, Bethesda, MD 20892 USA
[4] St Joseph Mercy Hosp, Ann Arbor, MI 48104 USA
关键词
anticoagulants; atrial fibrillation; stroke prevention;
D O I
10.1161/01.STR.0000035260.70403.88
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and Purpose-The emergency department (ED), as the point of first medical contact for many complaints referable to atrial fibrillation (AF) and a common source of primary care, occupies a unique position to identify AF patients at risk of stroke. This study evaluates that potential by determining the prevalence of AF in an ED population and assessing antithrombotic use in those patients with recurrent AF. Methods-This was a multicenter, retrospective, cross-sectional study of consecutive records of ED patients with AF identified by ECG between January and June 1998. American Heart Association and modified Stroke Prevention in Atrial Fibrillation criteria established high-risk patients and contraindications to anticoagulation, respectively. Results-We identified 866 records with ECG-proven AF in 78 787 patient visits for an estimated prevalence of 1.10% (95% CI, 1.03 to 1.17). We found that 556 records had a prior history of AF; of these, 221 (40%) used warfarin alone, 155 (28%) had antiplatelet therapy alone, 28 (5%) used both, and 152 (27%) had no antithrombotic therapy identified. Sixty-eight patients (12%; 95% CI, 0.10 to 0.15) were warfarin eligible and without antithrombotic therapy. An additional 64 (12%; 95% CI, 0.09 to 0.14) had antiplatelet therapy alone. In warfarin-eligible patients, no differences were identified between the anticoagulated and nonanticoagulated groups on the basis of age, sex, or race. Of patients on warfarin with a measured international normalized ratio, 61% (95% CI, 0.55 to 0.67) were outside the AHA-recommended range of 2.0 to 3.0. Conclusions-AF is a common finding in an ED population. Many are warfarin eligible and untreated or under-treated. Methods to increase anticoagulant use in this at-risk population warrant further investigation.
引用
收藏
页码:2664 / 2669
页数:6
相关论文
共 30 条
[1]   STROKE PREVENTION IN NONVALVULAR ATRIAL-FIBRILLATION [J].
ALBERS, GW ;
ATWOOD, JE ;
HIRSH, J ;
SHERMAN, DG ;
HUGHES, RA ;
CONNOLLY, SJ .
ANNALS OF INTERNAL MEDICINE, 1991, 115 (09) :727-736
[2]   Intravenous tissue-type plasminogen activator for treatment of acute stroke - The standard treatment with alteplase to reverse stroke (STARS) study [J].
Albers, GW ;
Bates, VE ;
Clark, WM ;
Bell, R ;
Verro, P ;
Hamilton, SA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (09) :1145-1150
[3]   Status of antithrombotic therapy for patients with atrial fibrillation in university hospitals [J].
Albers, GW ;
Yim, JM ;
Belew, KM ;
Bittar, N ;
Hattemer, CR ;
Phillips, BG ;
Kemp, S ;
Hall, EA ;
Morton, DJ ;
Vlasses, PH .
ARCHIVES OF INTERNAL MEDICINE, 1996, 156 (20) :2311-2316
[4]   PREDICTORS OF THROMBOEMBOLISM IN ATRIAL-FIBRILLATION .1. CLINICAL-FEATURES OF PATIENTS AT RISK [J].
ANDERSON, DC ;
ASINGER, RW ;
NEWBURG, SM ;
FARMER, CC ;
WANG, K ;
BUNDLIE, SR ;
KOLLER, RL ;
JAGIELLA, WM ;
KREHER, S ;
JORGENSEN, CR ;
SHARKEY, SW ;
FLAKER, GC ;
WEBEL, R ;
NOLTE, B ;
STEVENSON, P ;
BYER, J ;
WRIGHT, W ;
CHESEBRO, JH ;
WIEBERS, DO ;
HOLLAND, AE ;
MILLER, DM ;
BARDSLEY, WT ;
LITIN, SC ;
MEISSNER, I ;
ZERBE, DM ;
MCANULTY, JH ;
MARCHANT, C ;
COULL, BM ;
FELDMAN, G ;
HAYWARD, A ;
GANDARA, E ;
MACMILLAN, K ;
BLANK, N ;
LEONARD, AD ;
KANTER, MC ;
ISENSEE, LM ;
QUIROGA, ES ;
PRESTI, CH ;
TEGELER, CH ;
LOGAN, WR ;
HAMILTON, WP ;
GREEN, BJ ;
BACON, RS ;
REDD, RM ;
CADELL, DJ ;
GOMEZ, CR ;
JANOSIK, DL ;
LABOVITZ, AJ ;
KELLEY, RE ;
CHAHINE, R .
ANNALS OF INTERNAL MEDICINE, 1992, 116 (01) :1-5
[5]  
BURT CW, 2001, VITAL HLTH STAT, V13, P1
[6]   Intravenous tissue plasminogen activator for acute ischemic stroke: Feasibility, safety, and efficacy in the first year of clinical practice [J].
Chiu, D ;
Krieger, D ;
Villar-Cordova, C ;
Kasner, SE ;
Morgenstern, B ;
Bratina, PL ;
Yatsu, FM ;
Grotta, JC .
STROKE, 1998, 29 (01) :303-303
[7]   PREVALENCE, AGE DISTRIBUTION, AND GENDER OF PATIENTS WITH ATRIAL-FIBRILLATION - ANALYSIS AND IMPLICATIONS [J].
FEINBERG, WM ;
BLACKSHEAR, JL ;
LAUPACIS, A ;
KRONMAL, R ;
HART, RG .
ARCHIVES OF INTERNAL MEDICINE, 1995, 155 (05) :469-473
[8]   ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation:: Executive summary -: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients with Atrial Fibrillation) [J].
Fuster, V ;
Rydén, LE ;
Asinger, RW ;
Cannom, DS ;
Crijns, HJ ;
Frye, RL ;
Halperin, JL ;
Kay, GN ;
Klein, WW ;
Lévy, S ;
McNamara, RL ;
Prystowsky, EN ;
Wann, LS ;
Wyse, DG ;
Gibbons, RJ ;
Antman, EM ;
Alpert, JS ;
Faxon, DP ;
Fuster, V ;
Gregoratos, G ;
Hiratzka, LF ;
Jacobs, AK ;
Russell, RO ;
Smith, SC ;
Klein, WW ;
Alonso-Garcia, A ;
Blomström-Lundqvist, C ;
De Backer, G ;
Flather, M ;
Hradec, J ;
Oto, A ;
Parkhomenko, A ;
Silber, S ;
Torbicki, A .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 38 (04) :1231-1265
[9]   Prevalence of diagnosed atrial fibrillation in adults - National implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study [J].
Go, AS ;
Hylek, EM ;
Phillips, KA ;
Chang, YC ;
Henault, LE ;
Selby, JV ;
Singer, DE .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (18) :2370-2375
[10]   Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta-analysis [J].
Hart, RG ;
Benavente, O ;
McBride, R ;
Pearce, LA .
ANNALS OF INTERNAL MEDICINE, 1999, 131 (07) :492-+